Adès, Lionel

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

Sanz, M. A., Fenaux, P., Tallman, M. S., Estey, E. H., Löwenberg, B., Naoe, T., Lengfelder, E., Döhner, H., Burnett, A. K., Chen, S.-J., et al. (2019) · Blood

Retinoids in leukemia and cellular processesAcute Myeloid Leukemia Research

Cited by 664

Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure

Prébet, T., Gore, S. D., Esterni, B., Gardin, C., Itzykson, R., Thepot, S., Dreyfus, F., Rauzy, O. B., Recher, C., Adès, L., et al. (2011) · Journal of Clinical Oncology

Acute Myeloid Leukemia ResearchHematopoietic Stem Cell Transplantation

Cited by 475

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

for the International Working Group for MDS Molecular Prognostic Committee, Haase, D., Stevenson, K. E., Neuberg, D., Maciejewski, J. P., Nazha, A., Sekeres, M. A., Ebert, B. L., Garcia-Manero, G., Haferlach, C., et al. (2019) · Leukemia

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 259

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine

Bally, C., Adès, L., Renneville, A., Sebert, M., Eclache, V., Preudhomme, C., Mozziconacci, M.-J., de The, H., Lehmann-Che, J., & Fenaux, P. (2014) · Leukemia Research

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 162

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

Adès, L., Girshova, L., Doronin, V. A., Díez-Campelo, M., Valcárcel, D., Kambhampati, S., Viniou, N.-A., Woszczyk, D., De Paz Arias, R., Symeonidis, A., et al. (2022) · Blood Advances

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 130

A variant erythroferrone disrupts iron homeostasis in SF3B1 -mutated myelodysplastic syndrome

Bondu, S., Alary, A.-S., Lefèvre, C., Houy, A., Jung, G., Lefebvre, T., Rombaut, D., Boussaid, I., Bousta, A., Guillonneau, F., et al. (2019) · Science Translational Medicine

Acute Myeloid Leukemia ResearchIron Metabolism and Disorders

Cited by 85

A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML:GFM's “pick a winner” trial, with the impact of somatic mutations

Adès, L., Duployez, N., Guerci‐Bresler, A., Laribi, K., Peterlin, P., Vey, N., Thepot, S., Wickenhauser, S., Zerazhi, H., Stamatoullas, A., et al. (2022) · British Journal of Haematology

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 21